Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders

• ClinicalTrials.gov Identifier: NCT03344419
• Recruitment Status: Recruiting
• First Posted: November 17, 2017
• Last Update Posted: February 5, 2020
• Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute on Drug Abuse (NIDA)
• Information provided by (Responsible Party): Elias Dakwar, New York State Psychiatric Institute

Tracking Information

• First Submitted Date: November 13, 2017
• First Posted Date: November 17, 2017
• Last Update Posted Date: February 5, 2020
• Actual Study Start Date: October 1, 2017
• Estimated Primary Completion Date: April 2021 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: November 13, 2017): Abstinence from Cocaine Use [ Time Frame: from baseline to week 12 ]
• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
• Official Title: Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
• Brief Summary: Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based relapse prevention (MBRP) for cocaine use disorders.

Detailed Description

Alterations in the transmission between neurons of a neurotransmitter called glutamate are an important target of pharmacotherapy for cocaine use disorders (CUDs). Preliminary investigations suggest that glutamate modulation may be effective at promoting and maintaining abstinence and that it promotes motivation to quit, reduces craving, reduces cocaine self-administration and facilitates abstinence in individuals with a CUD in a series of trials.

The study team has recently developed and tested a novel design that integrates a clinical trial involving serial infusions and a behavioral treatment platform. The current trial will evaluate the effect of two sub-anesthetic infusions on abstinence rates in a relatively large sample of treatment-seeking CUD individuals who complete a 12-week double-blind, randomized, controlled trial. It will also evaluate the correlation between clinical response and brain-derived neurotrophic factor (BDNF), a peripheral biomarker relevant to glutamate modulation antidepressant response. This project aims to expand on several years of promising preliminary data to rigorously evaluate the efficacy of this innovative pharmacological intervention integrated into a behavioral treatment platform.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Cocaine Use Disorder

Intervention

• Drug: CI-581a
  Medication infusion intravenously over 1 hour.
• Drug: CI-581b
  Medication infusion intravenously over 1 hour.
• Behavioral: Motivational Enhancement Therapy (MET)
  Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
• Behavioral: Mindfulness Based Relapse Prevention
  Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.

Study Arms

• Experimental: CI-581a+MET+MBRP
  Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
  Interventions:

  • Drug: CI-581a
  • Behavioral: Motivational Enhancement Therapy (MET)
  • Behavioral: Mindfulness Based Relapse Prevention
• Active Comparator: CI-581b+MET+MBRP
  Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
  Interventions:

  • Drug: CI-581b
  • Behavioral: Motivational Enhancement Therapy (MET)
  • Behavioral: Mindfulness Based Relapse Prevention

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: November 13, 2017): 150
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: April 2021
• Estimated Primary Completion Date: April 2021 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Meets DSM-V criteria for cocaine use disorders, with at least 1 day of use per week over the past 30 days
2. Physically healthy
3. No adverse reactions to study medications
4. 21-69 years of age (including a score > 24 on the Mental Mini Status Exam for individuals over 60 years of age)
5. Capacity to consent and comply with study procedures
6. Seeking Treatment

Exclusion Criteria:

1. Meets DSM IV criteria for current major depression, bipolar disorder, schizophrenia, any psychotic illness, including substance induced psychosis, and current substance-induced mood disorder with HAMD score > 12.
2. Physiological dependence on another substance, such as alcohol, opioids, or benzodiazepines, excluding caffeine and nicotine
3. Delirium, Dementia, Amnesia, Cognitive Disorders, or Dissociative disorders
4. Current suicide risk or a history of suicide attempt within the 2 years
5. Pregnant, interested in becoming pregnant, or lactating
6. On psychotropic or other medication whose effect could be disrupted by participation in the study, such as benzodiazepines, opioids, or barbiturates
7. Recent history of significant violence (past 2 years)
8. Heart disease as indicated by history, abnormal ECG, previous cardiac surgery.
9. Unstable physical disorders which might make participation hazardous such as end-stage AIDS, hypertension (>140/90), anemia, active hepatitis or other liver disease (transaminase levels < 2-3 X the upper limit of normal will be considered acceptable), or untreated diabetes
10. Previous history of ketamine or benzodiazepine abuse, and/or a history of adverse reaction/experience with prior exposure to ketamine or benzodiazepines

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 21 Years to 60 Years (Adult)
• Accepts Healthy Volunteers: Yes

Contacts

Contact: Elias Dakwar, MD; 646-774-6117; elias.dakwar@nyspi.columbia.edu

Contact: Ryan Fox; ryan.fox@nyspi.columbia.edu

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03344419
• Other Study ID Numbers: 7461
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Responsible Party: Elias Dakwar, New York State Psychiatric Institute
• Study Sponsor: New York State Psychiatric Institute
• Collaborators: National Institute on Drug Abuse (NIDA)
• Investigators: Not Provided
• PRS Account: New York State Psychiatric Institute
• Verification Date: January 2020